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Abstract: Male infertility is a global health issue; yet to a large extent, our knowledge of its causes, impact and consequence is largely
unknown. Recent data indicate that infertile men have an increased risk of somatic disorders such as cancer and die younger compared to
fertile men. Moreover, several studies point to a significant adverse effect on the health of the offspring. From the startling lack of progress
in male contraception combined with the paucity of improvements in the diagnosis of male infertility, we conclude there is a crisis in
male reproductive health. The Male Reproductive Health Initiative has been organized to directly address these issues (www.eshre.eu/
Specialty-groups/Special-Interest-Groups/Andrology/MRHI). The Working Group will formulate an evidence-based strategic road map
outlining the ways forward. This is an open consortium desiring to engage with all stakeholders and governments.
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Background and scientific
rational
Male infertility is a global health problem. Meta-analysis data provide
evidence for a decline in human testicular sperm production in many
populations of around 1.6% per year between 1973 and 2011 (Levine
et al., 2017). Global statistics on the prevalence of male infertility indi-
cate that up to 12% of men are infertile (Agarwal et al., 2015, Cairo
Consensus Workshop Group, 2020). Raising additional concerns are
emerging reports showing that infertile men carry a higher disease bur-
den, with an increased risk of incident disease (including heart disease
and cancer) and die younger compared to fertile men (Kasman et al.,
2020a). Male infertility has therefore been termed a ‘harbinger of
future morbidity and mortality’ (Stentz et al., 2020) and is a health
problem of growing global importance. Further, there is increasing
evidence that the health of the father may have significant effects
on the health of offspring (Kasman et al., 2020b). Moreover, we now
understand that the paternal epigenome can be significantly influenced
by the environment and this can be manifested in the health of the
offspring (e.g. Soubry, 2018). All of the aforementioned issues combine
to provide a wake-up call for the crisis in male reproductive health
and an urgent need to act (De Jonge and Barratt, 2019).
†The authors consider that the first two authors should be regarded as joint first authors.
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What is required to address these issues? Critical arguments for a
strategic approach for Male Reproductive Health (MRH) have been
presented by several authors (Barratt et al., 2017, 2018, Skakkebaek
et al., 2019; De Jonge and Barratt, 2019; Ravitsky and Kimmins, 2019).
An important starting point was to develop a global MRH Initiative
(MRHI; De Jonge and Barratt, 2019) that aims to provide a road map
to address emerging concerns for male reproductive health. To de-
velop the MRHI road map, the authors have assembled as a multidisci-
plinary Working Group.
Goals of the global male
reproductive health road map
What are the important time-sensitive
research questions?
Remarkably, we still only have a basic understanding of the production,
formation and function of a human spermatozoon. It is fundamental to
understand these cellular, molecular, biochemical and genetic
mechanism(s) to develop actionable intervention strategies and
clinically relevant diagnostic assays that will assist in guiding more
effective therapeutic approaches for male infertility.
There is evidence that poor male reproductive health is associated
with poor overall health and early death (Kasman et al., 2020a). What
is the nature of this relationship? How can we untangle ‘cause and ef-
fect’ for this association?
How can we examine the impact of MRH on any offspring con-
ceived naturally or through Medically Assisted Reproduction (MAR)?
Moreover, compelling data are emerging that the environment (diet,
toxicants and body mass index) can induce changes in the sperm epi-
genome and that these changes can be transmitted to the embryo to
influence development and health (Donkin et al., 2016; Ly et al., 2017;
Lismer et al., 2020). This epigenetic contribution to the offspring sug-
gests intergenerational biological effects driven by sperm. Important
questions to address include (i) how does the epigenetic profile of the
paternal genome become modified by environmental exposures such
that health of the offspring is affected? (ii) is it possible to reverse envi-
ronmentally induced epigenome changes to the sperm? (iii) does re-
moval from environmental exposure(s) ameliorate the cause and effect
or does the effect remain over multiple spermatogenic cycles or even
a lifetime? and (iv) since it is well established that paternal aging con-
tributes to genetic disease in the offspring, what are the mechanisms
and are they treatable?
Work by other groups is contributing to formulating detailed key
MRH research questions, for example, the WHO Expert Synthesis
Group (Barratt et al., 2017) and the Priority Setting Partnership for
Infertility that has presented their top infertility research questions
(Duffy et al., 2020). In fact, it is essential that both broad and narrow
scoping of literature data inform additional research questions to fur-
ther support MRH.
What experimental strategies can be used
to answer the research questions?
While identifying research questions is a challenge, outlining realistic
experimental design approaches to address them is significantly more
difficult. Firstly, cohort investigational studies should be diverse in the
ethnicity of men, geographic locations and socio-economic status.
Further, how do we address some of the above questions in a real-
world manner? How can current experimental methods be identified
as effective? What limitations are present at experimental and organi-
zational levels? What animal models might be helpful and in what con-
text? How relevant are in vitro models and what new models of
relevance could be developed? What existing data/repositories can
address the questions (preclinical, genetic, national repositories, etc.)?
What methodologies should be standardized and can investigational
approaches be utilized from other disciplines? Is there an adequate re-
source of young investigators with appropriate training to address the
growing research agenda? If not, how can a research career in MRH
be promoted to reach the necessary capacity?
Enhancing and suppressing male fertility
The burdens of both infertility treatment and fertility control continue
to fall disproportionately upon women. New intervention strategies
and treatment approaches aiming to improve male fertility would lead
to a lesser requirement for women having to undergo MAR. What
new treatments are in development and what barriers prevent
progress?
The lack of effective, reversible male contraceptive methods is unac-
ceptable, and it further perpetuates suppression of female freedom
and economic growth in some regions of the world (Reynolds-Wright
and Anderson, 2019). There is an urgent need and market demand
for additional male contraceptive options but how can this be realized?
There is a nascent resurgence of interest in male contraception under
the auspices of, for example, the Bill and Melinda Gates Foundation
(www.gatesfoundation.org/What-We-Do/Global-Development/
Family-Planning) and NICHD (https://www.nichd.nih.gov/about/
org/der/branches/crb). Moreover, there are now specific organiza-
tions for male contraception, for example, the Male Contraceptive
Initiative (www.malecontraceptive.org/). Is there potential for syn-
ergy between the MRHI road map and these organizations?
Global engagement of males, their
partners and policymakers in MRH
Data show the need for greater involvement of men in their reproduc-
tive health and beginning early in their adult life (Hammarberg et al.,
2017, Prior et al., 2019). For that to happen requires re-evaluation
and, likely, redesign for how men are educated about their reproduc-
tive health. It also requires increased social awareness and education.
This includes strategies to better engage men and their partners with,
for example, medical and mental health professionals about MRH.
Doing so will subsequently impact on public engagement, understand-
ing and support. Collaborations with key stakeholders, such as Fertility
Europe (http://www.fertilityeurope.eu/) and Resolve (https://resolve.
org/), to examine information, research and strategy are necessary in
this arena. Moreover, in this context, it would be valuable to assess
the key strategies that have contributed to the success of campaigns
aimed at examining male health in general, such as Movember
(https://uk.movember.com) and Prostate Cancer UK https://prostate
canceruk.org/. What are the overlaps/synergies of MRH with wider
issues in men’s health? There are a few established initiatives across

























































































































































































































































the globe, for example, Global Action on Men’s Health (https://gamh.
org/), Healthy Male (formerly Andrology Australia, https://www.
healthymale.org.au/) and the Men’s Health Forum Ireland from the
Republic of Ireland which became the first country in the world to
publish a National Men’s Health Policy (https://www.mhfi.org/).
Affecting MRH research and education strategies is necessary but in-
sufficient in isolation. Policy change is required. This involves forming
fundamental strategic alliances, development of strategic methods and
identification and assessment of funding streams (current and future).
This necessitates discussion with a range of stakeholders, for example,
policymakers, industry and funders. Establishing collaborations with
government and health policymakers will drive associated funding
agencies to invest in MRH. Moreover, we can learn by assessing how
other disciplines have successfully addressed significant challenges to le-
verage complementary expertise and funding, for example, the Human
Biomolecular Atlas (HuBMAP Consortium, 2019).
Challenges to delivery of an
MRHI road map and ways of
mitigating their impact
Resources
Any potentially socially transformative initiative is dependent on dedi-
cated people, substantial time commitment and financial support.
Informal discussions with key opinion leaders, professional societies
(e.g. American Society of Andrology, Canadian Fertility and Andrology
Society, IFFS, ASPIRE, Fertility Society of Australia, Society for
Reproductive Biology (Australia and New Zealand)), funding agencies
(e.g. NIH, Wellcome Trust) and industry strongly suggested that a
global approach is needed and would attract significant support.
However, almost all discussants wanted to first see the initiative de-
velop and gain traction before they would consider committing resour-
ces or offer significant assistance. To address this, the MRHI submitted
a grant proposal to the European Society for Human Reproduction
and Embryology (ESHRE) for financial support to lay necessary ground-
work for the initiative. The proposal was approved by ESHRE and the
funds will be used by the Working Group to hold essential in-person
meetings to galvanize the road map. Furthermore, the European
Academy of Andrology (EAA) will provide support to assist with
Working Group meetings and stakeholder conferences. Productivity
outputs resulting from these funding sources will provide supportive
evidence to better leverage more substantive and long-term funding
from other sources, such as societies, funders, industry and private
organizations. Development of a web presence is critical for visibility
to promote the initiative, stimulate interest and create opportunities
for collaboration (www.eshre.eu/Specialty-groups/Special-Interest-
Groups/Andrology/MRHI). The goals are ultimately to globally influ-
ence society, education and legislative policymakers about the signifi-
cance of MRH.
Low starting base
Fundamentally, there is much intelligence gathering required. As illus-
trated by the WHO Expert Scanning Group analysis (Barratt et al.,
2017), the starting base is relatively low. Foundational data are
required to build on our knowledge and even challenge whether our
perceptions are correct. For example, is it correct to assume that a
lack of funding for studies into the biology underlying male infertility
(Table I) has negatively impacted upon diagnostic investigations and
clinical management? In fact, what is the worldwide funding level for
MRH? What clinical trials are ongoing? How effective is patient infor-
mation on male infertility in different countries? What clinical cohorts
and tissues repositories are available? Initial data addressing some of
these questions are instructive (Table I; https://www.nihr.ac.uk/docu
ments/reproductive-health-and-childbirth-specialty-profile/12117?diary
entryid¼45412#Track_record). For example, examination of data
from clinicaltrials.gov shows that there are 239 trials currently recruit-
ing for female infertility and 223 trials currently recruiting for male in-
fertility. However, of these ‘male infertility’ trials, 154 (69%) deal with
female infertility, 20 (9%) deal with IVF and two deal with offspring
only. Thus, there are 47 trials all over the world actively recruiting for
male infertility compared to hundreds for female infertility.
Paucity of regional and national strategies
Given the limited activity in the MRH space to date, it is perhaps not
surprising that there are only a few examples of a nationally or globally
coordinated approach among the 193 UN Nation Member States.
The Australian ‘Healthy Male’ (https://www.healthymale.org.au/), op-
erating since 2000, was recently approached by the Australian
Government to oversee the updating of the National Male Health
Policy. This successful engagement reflected Healthy Male’s standing as
a source of evidence-based quality advice. It is evident that MRH is a
way of garnering attention in the health sector, which then allows a
broadening of influence into other related health domains, especially
regarding chronic disease and those underlying the social determinants
of health, such as education, justice and employment
Summary and conclusion
Male infertility is a spectrum of diseases of global significance. It, like
many other conditions, will be impacted by genetic and environmental
change; the identity of these insults and consequences, however, re-
main largely unexplored. In contrast to most other diseases, MRH has
the potential to affect offspring health and, as such, the health of global
populations. This, and the absence of safe and reversible male contra-
ceptives, makes an investment in research and education an urgent pri-
ority of relevance to all genders. The current status quo leads to the
burden of family planning and infertility treatment being unacceptably
placed on the female partner. To address this gap, the authors have
formed the MRHI. This is an open consortium desiring to engage with
all stakeholders and governments.
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